Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Change in Account Payables (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Change in Account Payables for 6 consecutive years, with $4.3 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 193.84% to $4.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.8 million through Dec 2025, up 677.61% year-over-year, with the annual reading at $6.8 million for FY2025, 677.61% up from the prior year.
  • Change in Account Payables for Q4 2025 was $4.3 million at 4D Molecular Therapeutics, up from -$1.8 million in the prior quarter.
  • The five-year high for Change in Account Payables was $4.5 million in Q2 2025, with the low at -$1.8 million in Q3 2025.
  • Average Change in Account Payables over 5 years is $459350.0, with a median of $327500.0 recorded in 2021.
  • The sharpest move saw Change in Account Payables crashed 313.46% in 2022, then surged 678.75% in 2025.
  • Over 5 years, Change in Account Payables stood at $1.7 million in 2021, then dropped by 8.97% to $1.5 million in 2022, then tumbled by 171.91% to -$1.1 million in 2023, then skyrocketed by 234.38% to $1.5 million in 2024, then skyrocketed by 193.84% to $4.3 million in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at $4.3 million, -$1.8 million, and $4.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.